Trevena (NASDAQ:TRVN – Get Free Report) is projected to post its results before the market opens on Wednesday, February 25th. Analysts expect Trevena to post earnings of $0.18 per share and revenue of $3.00 million for the quarter.
Trevena Price Performance
TRVN stock opened at $0.01 on Monday. The company has a market cap of $10,644.90, a PE ratio of 0.00 and a beta of 0.63. The business has a 50-day simple moving average of $0.01 and a 200 day simple moving average of $0.06. Trevena has a 52 week low of $0.00 and a 52 week high of $1.93.
Trevena Company Profile
Trevena, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of biased ligand G protein-coupled receptor (GPCR) selective medicines. By leveraging its proprietary bias-ligand technology platform, Trevena aims to create therapies that preferentially activate beneficial signaling pathways while minimizing engagement of pathways linked to adverse effects. The company’s research efforts target areas of high unmet medical need, including pain management, cardiometabolic disorders and central nervous system conditions.
The company’s lead compound, oliceridine (also known by its brand name OLINVEO), is a G protein-biased μ-opioid receptor agonist designed for the treatment of moderate to severe acute pain in the hospital setting.
Featured Articles
- Five stocks we like better than Trevena
- The gold chart Wall Street is terrified of…
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.
